MYGN
Myriad Genetics Inc
4.50$
+11.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -0.2% | -3.1% | -2.3% | -0.4% | -5.0% | -2.1% | -32.7% | +7.5% | -3.0% | -4.7% | -5.2% | |
| – | +18.2% | -7.4% | +0.4% | +0.5% | +1.6% | -3.6% | -1.0% | +21.3% | -3.5% | -6.0% | -7.6% | |
| – | +73.8% | -26.6% | -4.6% | +8.1% | +2.5% | -10.4% | -19.0% | +95.4% | +2.9% | -16.8% | -7.4% | |
| – | +63.3% | -26.0% | -6.7% | +2.7% | +2.5% | -10.4% | -19.0% | +95.4% | +2.9% | -16.8% | -7.4% | |
| – | -0.8% | +3.3% | -0.3% | +6.7% | -3.6% | -0.7% | +13.8% | -13.9% | -2.3% | +7.4% | -11.6% | |
| – | -12.4% | +11.8% | +6.1% | +0.4% | +5.0% | +2.9% | +1.4% | +10.1% | -3.2% | -8.8% | +9.7% | |
| – | +0.3% | -0.1% | -0.2% | +0.0% | +0.0% | +0.0% | -82.0% | +0.0% | +0.0% | -8.7% | +0.0% | |
| – | -2.0% | -2.5% | -6.3% | -2.2% | -16.0% | -1.9% | -34.2% | -3.8% | -5.9% | -5.0% | -4.6% | |
| – | -22.0% | -3.5% | -1.7% | +1.5% | -6.6% | -7.7% | -4.0% | +22.9% | -4.7% | -0.7% | -0.4% | |
| – | -25.5% | -6.3% | +1.9% | +3.6% | +6.4% | -7.9% | +32.3% | -26.0% | -9.6% | -2.7% | +0.4% | |
| – | -9.0% | -14.8% | -3.6% | +1.5% | -5.2% | -14.8% | +527.5% | -88.5% | -12.7% | +2.9% | +2.8% | |
| – | -23.9% | +28.3% | +0.6% | -11.1% | +9.1% | -13.0% | +10.0% | +2.9% | -5.7% | +8.7% | -6.7% | |
| – | +0.0% | +0.5% | +0.3% | +0.5% | +1.5% | +49.7% | – | – | +0.3% | +0.3% | +0.3% | |
| – | +14.6% | -3.0% | -2.6% | -1.2% | -4.2% | +0.5% | -44.9% | -3.9% | -1.3% | -8.3% | -9.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.1% | +4.4% | +0.8% | +0.3% | +0.2% | +0.3% | +1.2% | +0.6% | +0.2% | +0.4% | +1.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.